Furthermore, serum p62 exhibited a high overall accuracy in discriminating patients with NAFLD from control subjects and was reported as a potential non-invasive biomarker and an independent risk factor for the clinical diagnosis of NAFLD and NASH [46]. Here, SQSTM1 is linked to metabolic dysfunction-associated steatotic liver disease.